Searchable abstracts of presentations at key conferences in obesity

ob0002p8 | (1) | OU2020

Proglucagon peptide secretion post Roux-en-Y gastric bypass: one year prospective study

Alexiadou Kleopatra , Cuenco Joyceline , Howard James , Albrechtsen Nicolai Wewer , Ilesanmi Ibeyimi , Kamocka Anna , Tharakan George , Behary Preeshila , Ahmed Ahmed R , Holst Jens J , Bloom Stephen R , Khoo Bernard , Tan Tricia M

Background: Hyperglucagonaemia is one of the key players in the pathophysiology of type 2 diabetes. Roux-en-Y Gastric Bypass (RYGB) is currently a highly effective treatment for weight loss and diabetes remission. However, the role of glucagon in the above effects is unclear.Aim: To characterise the behaviour of proglucagon-derived peptides (glucagon, glucagon-like peptide-1, oxyntomodulin, glicentin) after RYGB surgery.Subjects an...

ob0003cd2.2 | Case Discussions 2 | OU2021

Glycaemic variability assessed by continuous glucose monitoring after Roux-en-Y gastric bypass vs. sleeve gastrectomy

Alexiadou Kleopatra , Malallah Khalefah , Ilesanmi Ibiyemi , Tabbakh Yasmin , Kenkre Julia , Choudhury Sirazum , Behary Preeshila , Tharakan George , Purkayastha Sanjay , Tsironis Christos , Hakky Sherif , Ahmed Ahmed R , Bloom Stephen R , Tan Tricia M

Background: Roux-en-Y Gastric Bypass (RYGB) and Sleeve Gastrectomy are two widely used bariatric procedures. Longitudinal data have shown similar efficacy in terms of sustained weight loss and diabetes remission in obese patients with type 2 diabetes. Altered glucose dynamics with increased glycaemic variability and the occurrence of hypoglycaemia are common post-bariatric surgery. Aim: To compare the glycaemic variability and incidence of hypoglycaemia ...

ob0004p3 | Presented Posters | OU2024

Proposed prioritisation framework for the introduction of new medical therapies for weight management in the NHS

Boyle Luke D , Albor Christo , Anyiam Oluwaseun , Sen Gupta Piya , Coelho Claudia , Crane James , K Dimitriadis Georgios , Andrews Robert , Hughes David , Idris Iskandar , Tan Tricia , M McGowan Barbara , McCullough Kath

Until recently, only two medications were licenced and approved by the National Institute of Health and Care Excellence (NICE) for weight loss, orlistat and liraglutide. Semaglutide 2.4mg was launched in September 2023. Both liraglutide and semaglutide belong to a class of drugs called GLP-1 analogues, also used in the treatment of Type 2 diabetes. Successful weight loss outcomes for GLP-1 analogues has led to increased global demand and shortages. In June 2023, a National Pat...